Opexa Therapeutics Company Profile (NASDAQ:OPXA)

Analyst Ratings

Consensus Ratings for Opexa Therapeutics (NASDAQ:OPXA) (?)
Ratings Breakdown: 3 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $11.67 (180.45% upside)

Analysts' Ratings History for Opexa Therapeutics (NASDAQ:OPXA)
Show:
DateFirmActionRatingPrice TargetActions
7/18/2016AegisBoost Price TargetBuy$11.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/3/2016Chardan CapitalReiterated RatingBuy$6.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/10/2016Maxim GroupReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/30/2014 forward)

Earnings

Earnings History for Opexa Therapeutics (NASDAQ:OPXA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/10/2016        
5/12/2016Q116($0.35)($0.31)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/15/2016Q415($0.50)($2.05)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2015Q315($2.48)($0.42)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2015Q215($0.08)($0.07)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2015Q1($0.15)($0.12)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/23/2015($0.14)($0.12)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/14/2014Q214($0.13)($0.15)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/14/2014Q114($0.13)($0.13)$0.22 million$0.35 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/14/2013Q213($0.37)$0.35 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/14/2012Q312($0.10)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Opexa Therapeutics (NASDAQ:OPXA)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Opexa Therapeutics (NASDAQ:OPXA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Opexa Therapeutics (NASDAQ:OPXA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
9/17/2014Timothy C BarabeDirectorBuy10,000$1.15$11,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/16/2014Neil K WarmaCEOBuy10,000$1.11$11,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/18/2013Karthik RadhakrishnanCFOBuy8,000$1.70$13,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/18/2013Scott B SeamanDirectorBuy30,000$1.70$51,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/8/2013Karthik RadhakrishnanCFOBuy50,000$1.50$75,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Opexa Therapeutics (NASDAQ:OPXA)
DateHeadline
07/19/16 05:46 PMHeightened Volatility Spotted on Shares of: Opexa Therapeutics, Inc. (NASDAQ:OPXA) - Engelwood Daily
07/19/16 05:46 PMHow Many Opexa Therapeutics Inc (NASDAQ:OPXA)'s Analysts Are Bullish? - Consumer Eagle
07/19/16 11:57 AMETF’s with exposure to Opexa Therapeutics, Inc. : July 19, 2016 -
07/19/16 06:52 AMOpexa Therapeutics, Inc. (NASDAQ:OPXA) Went Up 2.34%: Bovie Medical (NYSEMKT:BVX), Anworth Mortgage Asset ... - KC Register
07/17/16 05:03 PMOpexa Therapeutics Incorporated (NASDAQ:OPXA) Sellers Covered 21.6% of Their Shorts - Press Telegraph
07/15/16 10:40 AMNew Broker Ratings For Opexa Therapeutics, Inc. (OPXA) - FTSE News
07/14/16 05:56 PMStocks to Watch: Opexa Therapeutics, Inc. (NASDAQ:OPXA), GlobeImmune Inc. (NASDAQ:GBIM), Westlake Chemical ... - KC Register
07/12/16 09:58 AMStock Volatility Focus for: Opexa Therapeutics, Inc. (NASDAQ:OPXA) - Engelwood Daily
07/10/16 05:00 PMOpexa Therapeutics, Inc. (OPXA) Current Analyst Ratings - Fiscal Standard
07/07/16 05:42 PMCan Opexa Therapeutics Inc's Tomorrow Be Different? The Stock Increases Again - Press Telegraph
07/05/16 05:27 PM5 Best-Performing Biotech Stocks of June
07/02/16 08:27 AMWorth Watching Stocks: Duke Energy Corporation (NYSE:DUK), Opexa Therapeutics, Inc. (NASDAQ:OPXA), Sapiens ... - KC Register
07/02/16 08:27 AMOpexa Therapeutics Incorporated (NASDAQ:OPXA) Shorts Decreased by 21.6% After Short Covering - Engelwood Daily
07/01/16 04:19 PM5 Top Biotech Performers of 2016 -
06/28/16 05:37 PMHow Many Opexa Therapeutics Inc (NASDAQ:OPXA)'s Analysts Are Bearish? - Press Telegraph
06/28/16 05:37 PMCheck on Share Volatility: Opexa Therapeutics, Inc. (NASDAQ:OPXA) - Engelwood Daily
06/25/16 05:08 PMShare Volatility Check for: Opexa Therapeutics, Inc. (NASDAQ:OPXA) - Press Telegraph
06/25/16 05:08 PMOpexa Therapeutics, Inc. (OPXA) Updated Price Targets - FTSE News
06/21/16 10:03 AMInvestors Are Watching: Globalstar Inc. (NYSEMKT:GSAT), Opexa Therapeutics (NASDAQ:OPXA), Advanced Micro ... - KC Register
06/20/16 07:16 AMOpexa Therapeutics, Inc. (OPXA) Analyst Price Targets For The Coming Week - Fiscal Standard
06/16/16 09:53 AMManufacturing Industry Top Gainers, Biggest Losers Summary
06/11/16 05:50 PMEarnings Analysis to Watch: Banco Santander (NYSE:BSBR), Opexa Therapeutics, Inc. (NASDAQ:OPXA) - Beacon Chronicle
06/03/16 08:33 AMStrong Sell Calls Count For Opexa Therapeutics, Inc. (NASDAQ:OPXA) At 0 - Investor Newswire - Strong Sell Calls Count For Opexa Therapeutics, Inc. (NASDAQ:OPXA) At 0Investor NewswireOpexa Therapeutics, Inc. (NASDAQ:OPXA) has a total of 2 Strong Buy calls and 0 Strong Sell advises as of 2016-06-01. Zacks uses a rating procedure which assigns scores to stocks on a narrow 1-5 scale. When a stock gets a score of 1 or 2, it is ...and more »
05/28/16 01:27 PMAnalyst Recommendations on These Stocks: Computer Sciences (CSC), Opexa Therapeutics (OPXA) - Beacon Chronicle - Analyst Recommendations on These Stocks: Computer Sciences (CSC), Opexa Therapeutics (OPXA)Beacon ChronicleLast Trade: The Company closed its last session at $ 50.66yesterday with the gain of 42.10%. The market capitalization of the company is $ 7.12Billion, with the average Volume of $ 1.12Million. The stock currently has its 52-Week High range of $ 50 ...and more »
05/26/16 01:31 PMU.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.82% - The top performers on the NASDAQ Composite were Innocoll AG (NASDAQ:INNL) which rose 47.82% to 10.51, Opexa Therapeutics Inc (NASDAQ:OPXA) which was up 27.52% to settle at 3.290 and Sarepta Therapeutics Inc (NASDAQ:SRPT) which gained 26.63% to close at 23.350.
05/26/16 01:31 PMVery Green Follow-Through Session - On the downside, no stocks were down as much as a point on our main board. Checking the TheTechTrader.com percent-gain leaderboard, Opexa Therapeutics, Inc. (OPXA), on earnings, spiked to 4.29 this morning, before pulling back to 3.29, up 71 cents ...
05/26/16 01:31 PMOpexa Therapeutics Inc. (OPXA) Has Surged To Nearly A 6-Month High - Opexa Therapeutics Inc. (OPXA) has been rising steadily since the open of trade Wednesday and is now up 1.31 at $3.89 on the highest volume in 6 months. Opexa Therapeutics is adding to its gains from the previous session and has broken out to nearly a 6 ...
05/25/16 01:34 PMHealthcare Stocks to Lookout: Opexa Therapeutics Inc (NASDAQ:OPXA), Carbylan Therapeutics Inc (NASDAQ:CBYL ... - The Point Review - Healthcare Stocks to Lookout: Opexa Therapeutics Inc (NASDAQ:OPXA), Carbylan Therapeutics Inc (NASDAQ:CBYL ...The Point ReviewShares of Opexa Therapeutics Inc (NASDAQ:OPXA) flew 28.99% to $3.33 at 12:04 PM EDT. The stock attained the volume of 3.72 Million shares recently versus average trading volume of 24,389 shares. If we take a look on its volatility, 8.55 percent was ...Opexa Therapeutics Inc (NASDAQ:OPXA)'s Company Shares Increased 12.17% After High VolatilityWall Street Hints and Newsall 2 news articles »
05/24/16 02:01 PMNext Weeks Broker Price Targets For Opexa Therapeutics, Inc. (OPXA) - Share Trading News - Next Weeks Broker Price Targets For Opexa Therapeutics, Inc. (OPXA)Share Trading NewsOpexa Therapeutics, Inc. has a 50 day moving average of 2.40 and a 200 day moving average of 2.51. The stock's market capitalization is 14.95M, it has a 52-week low of 1.69 and a 52-week high of 5.84. The share price of the company (OPXA) was up ...and more »
05/21/16 01:21 PMRevenue Update on Opexa Therapeutics Inc(NASDAQ:OPXA) - Trade Calls - Revenue Update on Opexa Therapeutics Inc(NASDAQ:OPXA)Trade CallsOpexa Therapeutics Inc(NASDAQ:OPXA) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during After-hours on May 12, 2016. Company reported revenue of $726.29K. Analysts estimated a revenue of $400.00K. Earnings ...Opexa Therapeutics Incorporated (NASDAQ:OPXA) Short Interest Decreased By 4.44%Franklin Independentall 2 news articles »
05/18/16 03:07 PMOPEXA THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
05/18/16 02:03 PMMorning Alert: Comcast Corporation (NASDAQ:CMCSA), Opexa Therapeutics, Inc. (NASDAQ:OPXA), NuVasive, Inc ... - KC Register - Morning Alert: Comcast Corporation (NASDAQ:CMCSA), Opexa Therapeutics, Inc. (NASDAQ:OPXA), NuVasive, Inc ...KC RegisterOpexa Therapeutics, Inc. (NASDAQ:OPXA) reported financial results for the quarter ended March 31, 2016. Net loss reported for the quarter ended March 31, 2016 was $2,160,394, or $.31 per share (basic and diluted), compared with a net loss of $3,350,880 ...
05/18/16 12:48 PMOpexa Therapeutics, Inc. :OPXA-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/14/16 07:36 AMBroker Roundup For Opexa Therapeutics, Inc. (OPXA) - Share Trading News - Broker Roundup For Opexa Therapeutics, Inc. (OPXA)Share Trading News03/24/2014 – Brinson Patrick began new coverage on Opexa Therapeutics, Inc. giving the company a “buy” rating. The share price of Opexa Therapeutics, Inc. (OPXA) was down -9.62% during the last trading session, with a day high of 2.38. 53997 shares ...Opexa Therapeutics' (OPXA) CEO Neil Warma on Q1 2016 Results - Earnings Call TranscriptSeeking AlphaOpexa Therapeutics (OPXA) Tops Q1 EPS by 4cStreetInsider.comOpexa Therapeutics Inc.: Opexa Therapeutics Reports First Quarter 2016 Financial Results and Provides Corporate ...The Wall Street Transcriptall 3 news articles »
05/13/16 08:02 AMOpexa Therapeutics' (OPXA) CEO Neil Warma on Q1 2016 Results - Earnings Call Transcript - Seeking Alpha - Opexa Therapeutics' (OPXA) CEO Neil Warma on Q1 2016 Results - Earnings Call TranscriptSeeking AlphaGood afternoon, everyone, and welcome to the Opexa Therapeutics first quarter conference call. During today's call, members of our Senior Management team will review Opexa's financial performance and business highlights for the quarter ending March 31, ...Opexa Therapeutics (OPXA) Tops Q1 EPS by 4cStreetInsider.comOpexa Therapeutics Inc.: Opexa Therapeutics Reports First Quarter 2016 Financial Results and Provides Corporate ...The Wall Street Transcriptall 3 news articles »
05/12/16 04:27 PMOpexa Therapeutics Reports First Quarter 2016 Financial Results and Provides Corporate Update - [at noodls] - Conference Call Scheduled Today at 4:30 PM ET THE WOODLANDS, TX -- (Marketwired) -- 05/12/16 -- Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies ...
05/12/16 03:10 PMOPEXA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and -
05/12/16 03:09 PMOPEXA THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report -
05/12/16 06:07 AMQ1 2016 Opexa Therapeutics Inc Earnings Release - After Market Close -
05/10/16 08:18 AMOpexa Therapeutics Announces News Release and Conference Call Schedule to Discuss First Quarter 2016 Financial Results - [at noodls] - THE WOODLANDS, TX -- (Marketwired) -- 05/10/16 -- Opexa Therapeutics, Inc. (NASDAQ: OPXA), a company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) ...
05/07/16 07:21 AMLatest Analyst Ratings For Opexa Therapeutics, Inc. (OPXA) - Share Trading News - Latest Analyst Ratings For Opexa Therapeutics, Inc. (OPXA)Share Trading NewsOpexa Therapeutics, Inc. has a 50 day moving average of 2.41 and a 200 day moving average of 2.58. The stock's market capitalization is 16.27M, it has a 52-week low of 1.69 and a 52-week high of 5.84. The share price of the company (OPXA) was up ...
04/27/16 09:15 AMOpexa Therapeutics, Inc. (OPXA) Analyst Review - Risers & Fallers - Opexa Therapeutics, Inc. (OPXA) Analyst ReviewRisers & FallersA number of investment brokers have recently updated their price targets on shares of Opexa Therapeutics, Inc. (OPXA). According to the latest broker reports outstanding on Wednesday 27th of April, 0 analysts have a rating of “strong buy”, 0 analysts ...
04/27/16 07:30 AMOpexa to Attend the Third International Conference on the Progress of Regenerative Medicine and Its Cultural Impact - [Marketwired] - Opexa Therapeutics, Inc. , a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including for multiple sclerosis and neuromyelitis optica , today announced that ...
04/25/16 08:31 AMAfter Last Week What Do Analysts Think Of Opexa Therapeutics, Inc. (OPXA) - Share Trading News - After Last Week What Do Analysts Think Of Opexa Therapeutics, Inc. (OPXA)Share Trading News03/24/2014 – Brinson Patrick began new coverage on Opexa Therapeutics, Inc. giving the company a “buy” rating. The share price of Opexa Therapeutics, Inc. (OPXA) was up +0.00% during the last trading session, with a day high of 2.49. 20182 shares were ...How Many Opexa Therapeutics Inc (NASDAQ:OPXA)'s Analysts Are Bearish?Franklin Independentall 2 news articles »
04/23/16 08:06 AMOpexa Therapeutics Incorporated (NASDAQ:OPXA) Short Interest Decreased By 3.35% - The Post - Opexa Therapeutics Incorporated (NASDAQ:OPXA) Short Interest Decreased By 3.35%The PostThe short interest to Opexa Therapeutics Incorporated's float is 3.29%. The stock decreased 1.64% or $0.04 on April 22, hitting $2.4. About 20,182 shares traded hands. Opexa Therapeutics Inc (NASDAQ:OPXA) has declined 37.50% since September 16, ...
04/22/16 08:50 AMBroker Changes For Opexa Therapeutics, Inc. (OPXA) - Risers & Fallers - Broker Changes For Opexa Therapeutics, Inc. (OPXA)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Opexa Therapeutics, Inc. (OPXA). The latest broker reports which are currently outstanding on Friday 22nd of April state 0 analysts have a rating of “strong buy”, 0 ...
04/21/16 08:53 AMBroker Outlook For Opexa Therapeutics, Inc. (OPXA) - Share Trading News - Broker Outlook For Opexa Therapeutics, Inc. (OPXA)Share Trading NewsOpexa Therapeutics, Inc. (Opexa) is a biopharmaceutical company developing a personalized immunotherapy with the potential to treat various illnesses, including multiple sclerosis (MS), as well as other autoimmune diseases, such as neuromyelitis optica ...
04/20/16 09:15 AMOpexa Therapeutics, Inc. (OPXA) Updated Broker Price Targets - Share Trading News - Opexa Therapeutics, Inc. (OPXA) Updated Broker Price TargetsShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Opexa Therapeutics, Inc. (OPXA). The latest reports which are currently in issue on Wednesday 20th of April state 0 analysts have a rating of “strong buy”, 0 analysts ...
04/19/16 09:13 AMCan Shares Of Opexa Therapeutics, Inc. (NASDAQ:OPXA) Hit $24.48? - Investor Newswire - Can Shares Of Opexa Therapeutics, Inc. (NASDAQ:OPXA) Hit $24.48?Investor NewswireThe Buy recommendations for Opexa Therapeutics, Inc. (NASDAQ:OPXA) stock is 1, sell recommendations at 0 and hold recommendations count at 0. It boasts a total of 2 Strong Buy calls and 0 Strong Sell calls as of 2016-04-18. One month ago, the strong ...and more »
03/19/16 12:04 PMOPEXA THERAPEUTICS, INC. Financials -

Social

About Opexa Therapeutics

Opexa Therapeutics logoOpexa Therapeutics, Inc. (Opexa) is a biopharmaceutical company. The Company is engaged in the development of a personalized immunotherapy with the potential to treat various illnesses, including multiple sclerosis (MS), as well as other autoimmune diseases, such as neuromyelitis optica (NMO). These therapies are based on its T-cell technology. The Company's product candidates include Tcelna and OPX-212. Tcelna is an autologous T-cell immunotherapy that is being developed for the treatment of secondary progressive MS (SPMS) and is tailored to each patient's immune response profile to myelin. Tcelna is designed to reduce the number and/or functional activity of specific subsets of myelin-reactive T-cells (MRTCs) known to attack myelin. Tcelna is manufactured using its method for the production of an autologous T-cell product. In addition to the ongoing clinical development of Tcelna, the Company is developing OPX-212 as an autologous T-cell immunotherapy for the treatment of NMO.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: OPXA
  • CUSIP:
Key Metrics:
  • Previous Close: $4.16
  • 50 Day Moving Average: $3.97
  • 200 Day Moving Average: $2.72
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $29.05M
  • Beta: 1.37
  • Current Year EPS Consensus Estimate: $-1.45 EPS
  • Next Year EPS Consensus Estimate: $-0.67 EPS
Additional Links:
Opexa Therapeutics (NASDAQ:OPXA) Chart for Saturday, July, 30, 2016